Publications by Epividian Scientists and Collaborators


Book Chapters

Fusco GP. Identifying Biomarker Profiles Through the Epidemiologic Analysis of Big Healthcare Data—Implications for Clinical Management and Clinical Trial Design: A Case Study of Anemia of Chronic Kidney Disease. In: Rahbari R, Van Niewaal J, Bleavins MR, editors. Biomarkers in Drug Discovery and Development: A Handbook of Practice, Application, and Strategy. 2nd ed. John Wiley & Sons, Inc. ISBN: 978-1-119-18750-9, April 2020.


Sension MG, Brunet L, Hsu RK, Fusco JS, Cochran Q, Uranaka C, Sridhar G, Vannappagari V, Van Wyk J, McCurdy L, Wohlfeiler MB, Fusco GP. Cabotegravir + Rilpivirine Long-Acting Injections for HIV Treatment in the US: Real World Data from the OPERA Cohort. Infect Dis Ther 2023.

Wohlfeiler MB, Weber RP, Brunet L, Siddiqui J, Harbour M, Phillips AL, Hayward B, Fusco JS, Hsu RK, Fusco GP. Incident HIV-Associated Wasting/Low Weight Is Associated with Nearly Doubled Mortality Risk in the Modern ART Era. AIDS research and human retroviruses 2024.

Pierone G, Jr., Brunet L, Fusco JS, Henegar CE, Sarkar S, Van Wyk J, Vannappagari V, Wohlfeiler MB, Fusco GP. Switching to Dolutegravir/Lamivudine Two-Drug Regimen: Durability and Virologic Outcomes by Age, Sex, and Race in Routine US Clinical Care. HIV AIDS (Auckl) 2024; 16:133-140.

Wohlfeiler MB, Brunet L, Cochran Q, Fusco JS, Hsu RK, Fusco GP. Improving Adherence to the Target Window for Cabotegravir + Rilpivirine Long-Acting Injections Through the CHORUS™ App and Web Portal: A Cluster Randomized Trial. Journal of the International Association of Providers of AIDS Care (JIAPAC) 2024; 23:23259582241245223.

Wohlfeiler MB, Weber RP, Brunet L, Siddiqui J, Harbour M, Phillips AL, Hayward B, Fusco JS, Hsu RK, Fusco GP. Definition, Burden, and Predictors of HIV-Associated Wasting and Low Weight in the OPERA® CohortAIDS research and human retroviruses; 2023.

Mounzer K, Brunet L, Fusco JS, McNicholl IR, Dunbar M, Sension M, McCurdy LH, Fusco GP. Immune response to ART initiation in advanced HIV infection. HIV Medicine. 2023; 1-11.

Hsu RK, Fusco JS, Henegar CE, Vannappagari V, Clark A, Brunet L, Lackey PC, Pierone G, Fusco GP. Heavily treatment-experienced people living with HIV in the OPERA® cohort: population characteristics and clinical outcomes. BMC Infectious Diseases 2023; 23(1):91.

Wohlfeiler MB, Weber RP, Brunet L, Fusco JS, Uranaka C, Cochran Q, Palma M, Evans T, Millner C, Fusco GP. HIV retention in care: results and lessons learned from the Positive Pathways Implementation Trial. BMC Primary Care 2022; 23(1):297.

Hsu RK, Brunet L, Fusco JS, Mounzer K, LaMori JC, Fusco GP. Excessive Weight Gain: Current Antiretroviral Agents in Virologically Suppressed People with HIV. AIDS research and human retroviruses. 2022; 38(10):782-791.

Pierone G, Fusco JS, Vannappagari V, et al. Dolutegravir/rilpivirine 2-drug regimen comparable to commonly prescribed 3-drug regimens up to 18-months in a real-world setting. Antiviral Therapy. 2022;27(1).

Mounzer K, Brunet L, Fusco FS, et al. Advanced HIV Infection in Treatment Naïve Individuals: Effectiveness and Persistence of Recommended Three-Drug Regimens. Open Forum Infectious Diseases. 2022;9(3):ofac018.

Mallon PWG, Brunet L, Fusco JS, et al. Lipid Changes After Switch From TDF to TAF in the OPERA Cohort: LDL Cholesterol and Triglycerides. Open Forum Infectious Diseases. 2022;9(1).

Mounzer KC, Fusco JS, Hsu RK, et al. Are We Hitting the Target? HIV Pre-Exposure Prophylaxis from 2012 to 2020 in the OPERA Cohort. AIDS Patient Care STDS. 2021;35(11):419-27.

Brunet L, Mallon P, Fusco JS, et al. Switch from Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living with HIV: Lipid Changes and Statin Underutilization. Clin Drug Investig. 2021;41(11):955-65.

Mills AM, Schulman KL, Fusco JS, et al. Virologic Outcomes among People Living with HIV with High Pre-Therapy Viral Load Burden Initiating on Common Core Agents. Open Forum Infectious Diseases. 2021;8(8):ofab363.

Mounzer K, Brunet L, Wyatt CM, et al. To dose-adjust or not to dose-adjust: lamivudine dose in kidney impairment. AIDS. 2021;35(8):1201-8.

Mounzer K, Brunet L, Hsu R, et al. Changes in Body Mass Index Associated with Antiretroviral Regimen Switch Among Treatment-Experienced, Virologically Suppressed People Living with HIV in the United States. AIDS Res Hum Retroviruses. 2021;37(11):852-61.

Mallon PW, Brunet L, Hsu RK, et al. Weight gain before and after switch from TDF to TAF in a U.S. cohort study. J Int AIDS Soc. 2021;24(4):e25702.

Hsu R, Brunet L, Fusco JS, et al. Incident type 2 diabetes mellitus after initiation of common HIV antiretroviral drugs. AIDS. 2021;35(1):81-90.

Hsu R, Brunet L, Fusco J, et al. Risk of chronic kidney disease in people living with HIV by tenofovir disoproxil fumarate (TDF) use and baseline D:A:D chronic kidney disease risk score. HIV Med. 2021;22(5):325-33.

Wohlfeiler M, Mounzer K, Brunet L, et al. Antiretroviral therapy and liver disorders in the OPERA® cohort. Therapeutic Advances in Drug Safety. 2020;11:1-12.

Brunet L, Wyatt C, Hsu R, Mounzer K, Fusco J, Fusco G. Assessing bias introduced in estimated glomerular filtration rate by the inhibition of creatinine tubular secretion from common antiretrovirals. Antivir Ther. 2020;25(5):287-92.

Mills AM, Schulman KL, Fusco JS, et al. Validation of the Data Collection on Adverse Events of Anti-HIV Drugs (D:A:D) chronic kidney disease risk score in HIV-infected patients in the USA. HIV Med. 2020;21(5):299-308.

Mills AM, Brunet L, Fusco JS, et al. Virologic Outcomes Among ART-Naïve Individuals Initiating Dolutegravir, Elvitegravir, Raltegravir or Darunavir: An Observational Study. Infect Dis Ther. 2020;9(1):41-52.

Pierone G, Henegar C, Fusco J, et al. Two-drug antiretroviral regimens: an assessment of virologic response and durability among treatment-experienced persons living with HIV in the OPERA® Observational Database. J Int AIDS Soc. 2019;22(12):e25418.

Fusco J, Henegar C, Quinlivan EB, et al. Integrase Inhibitor-Based Antiretroviral Therapy Among Women Living with HIV: Data from the OPERA Cohort. Curr HIV Res. 2019;17(4):266-76.

Heglar R, Mood R, Priest JL, Schulman KL, Fusco GP. Benchmarking HIV Quality Measures in the US OPERA HIV Cohort. Open Forum Infect Dis. 2019;6(10):ofz418.

Mounzer K, Hsu R, Fusco JS, et al. HLA-B*57:01 screening and hypersensitivity reaction to abacavir between 1999 and 2016 in the OPERA® observational database: a cohort study. AIDS Res Ther. 2019;16(1):1.

Hsu R, Fusco J, Henegar C, et al. Psychiatric outcomes observed in patients living with HIV using six common core antiretrovirals in the Observational Pharmaco-Epidemiology Research and Analysis database. Ther Adv Drug Saf. 2018;9(12):675-86.

Fusco G, Hariri A, Vallarino C, Singh A, Yu P, Wise L.  A threshold trajectory was revealed by isolating the effects of hemoglobin rate of rise in anemia of Chronic Kidney Disease. Adv. Drug Saf. 2017;8(10):305–318.

Fettiplace A, Stainsby C, Winston A, et al. Psychiatric Symptoms in Patients Receiving Dolutegravir. J Acquir Immune Defic Syndr. 2017;74(4):423-31.

Lackey P, Mills A, Carpio F, et al. Virologic Effectiveness of Abacavir/Lamivudine with Darunavir/Ritonavir Versus Other Protease Inhibitors in Treatment-Experienced HIV-Infected Patients in Clinical Practice. Clin Drug Investig. 2017;37(1):51-60.

Braithwaite RS, Justice AC, Chang CH, Fusco JS, Raffanti SR, Wong JB, Roberts MS. Estimating the proportion of individuals infected with Human Immunodeficiency Virus who will die of comorbid diseases. Am. J. Med. 2005;118(8):890-8.

Raffanti SR, Fusco JS, Sherrill BH, Hansen NI, Justice AC, Mangialardi WJ, D’Aquila R, Fusco GP. Effect of persistent moderate viremia on disease progression during HIV therapy. J. Acquir. Immune Defic. Syndr. 2004;37(1):1147-1154.

Becker SL, Feinberg J, Fusco JS, Balu RB, Gangjee S, Brennan C, Fusco GP. HIV-associated thrombotic microangiopathy in the post-HAART era: an observational study. Clin. Infect. Dis. 2004;39:S267-75.

Ledergerber B, Lundgren JD, Walker AS, Sabin C, Justice A, Reiss P, Mussini C, Wit F, d'Arminio Monforte A, Weber R, Fusco G, Staszewski S, Law M, Hogg R, Lampe F, Gill MJ, Castelli F, Phillips AN; PLATO Collaboration. Predictors of trend in CD4-positive mortality among HIV-1-infected individuals with virologic failure to all three antiretroviral drug classes. Lancet 2004;364(9428):51-62.

Justice AC, Stein DS, Fusco GP, Sherrill BH, Fusco JS, Danehower SC et al. Disease progression in HIV-infected patients treated with stavudine vs. zidovudine. J. Clin. Epidemiol. 2004;57(1):89-97.

King JT, Jr., Justice AC, Roberts MS, Chang CC, Fusco JS. Long-term HIV/AIDS survival estimation in the highly active antiretroviral therapy era. Med. Decis. Making 2003;23(1):9-20.

Becker SL, Raffanti SR, Hansen NI, Fusco JS, Fusco GP, Slatko GH, Igboko E, Graham N. Zidovudine and stavudine sequencing in HIV treatment planning. J. Acquir. Immune Defic. Syndr. 2001;26(1):72-81.